Loading...
Market
What level of transthyretin reduction will Intellia's CRISPR therapy achieve by end of 2025?
2
Resolution / Starting Odds
80% or less • 25%
81% to 89% • 25%
90% to 95% • 25%
More than 95% • 25%
Published peer-reviewed studies or clinical trial results
Story
Intellia's CRISPR Therapy Shows 90% Reduction in ATTR-CM Over 12 Months
Nov 18, 2024, 04:25 AM
Intellia Therapeutics has announced promising results from its ongoing Phase 1 study of its CRISPR therapy, nexiguran ziclumeran (nex-z), for treating transthyretin amyloidosis (ATTR-CM). The therapy demonstrated a 90% reduction in transthyretin levels over 12 months, indicating potential disease stabilization. This result is significant compared to Alnylam's siRNA therapy, which showed an 81% reduction. Additionally, Intellia's therapy showed gains in cardiomyopathy, further highlighting its efficacy.
View original story
Similar markets
Successful reduction in serum TTR levels • 25%
High adverse events lead to study halt • 25%
Modifications required for safety • 25%
Study continuation without major issues • 25%
Phase 2 Trial Completion • 25%
FDA Approval • 25%
Commercial Launch • 25%
None of the Above • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Yes • 50%
No • 50%
0-10 • 25%
11-20 • 25%
21-30 • 25%
More than 30 • 25%
By Q1 2025 • 25%
By Q2 2025 • 25%
By Q3 2025 • 25%
By Q4 2025 • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%